Hematologic Malignancy
T Acute Lymphoblastic Leukemia
CI-CAN-00004056T-ALLExplore in graph →
Hematologic47 active trials7 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004056T-ALLExplore in graph →
Clinical trials
117 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04315324 | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | active not recruiting | Phase 1 / Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 1, 2026 |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05602194 | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | active not recruiting | Phase 3 | 440 | Children's Oncology GroupNETWORK | 2 | Aug 21, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT02112916 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | active not recruiting | Phase 3 | 847 | National Cancer Institute (NCI)NIH | 4 | Jul 29, 2026 | clinicaltrials |
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | active not recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL(PD1-VEN-CAG) | active not recruiting | Phase 3 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program(DARATALL-VHR) | active not recruiting | Phase 2 | 31 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials